
Remibrutinib reduced relapse rates and improved disease progression rates

If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica

MS affects nearly three million people worldwide and has three main types

The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company

More than 186,000 men are diagnosed each year with mHSPC globally

The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe

Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates

The construction is part of the company’s investment in US research and manufacturing

The company has also opened its first dedicated genetic medicine facility in Indiana in the US

With a 10-day ceasefire between Israel and Lebanon in effect, oil prices are retreating from recent highs

Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases

The agreement will expand the pipeline and builds on an existing partnership